SUPREFACT

This brand name is authorized in Austria, Brazil, Canada, Netherlands, Singapore, South Africa, Spain, UK.

Active ingredients

The drug SUPREFACT contains one active pharmaceutical ingredient (API):

1	Buserelin UNII 13U86G7YSP - BUSERELIN ACETATE
	Buserelin is a synthetic peptide. It is a superactive analogue of natural gonadotrophin releasing hormone (gonadorelin, LHRH or GNRH). After an initial stimulation of gonadotrophin release, it down-regulates the hypothalanic-pituitary-gonadal axis.
	Read more about Buserelin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SUPREFACT Injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
SUPREFACT Nasal spray	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02AE01	Buserelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	502811901171315
CA	Health Products and Food Branch	02225158, 02225166, 02228955, 02240749
ES	Centro de información online de medicamentos de la AEMPS	57011, 60980, 62477
GB	Medicines & Healthcare Products Regulatory Agency	39293, 42572
NL	Z-Index G-Standaard, PRK	22756, 50997
SG	Health Sciences Authority	04362P
ZA	Health Products Regulatory Authority	32/21.10/0345, V/21.10/170